Company Overview and News

133
10 Best Stocks Under $10

2018-06-19 investorplace
Good things come in small packages goes the saying. Nowhere is that truer than in the markets where stocks under $10 grow to be $100 and possibly even $1,000 over time.
REG FCR.DB.H FCR.DB.I FXFLF WETF BXG VAC FXFHF FAXXF FCR.DB.J AY DXJ FSC GZT OAK HEDJ FRFHF OSLE FRFFF JILL SIRI ARCO AMZN OAK.PRA FRFZF FAXRF FRFXF FCR.DB.E MCD REG.PRG REG.PRF BBX IBN FRFGF AQN OCSL FCRGF GZT ICICIBANK FSCFL EDE 532174 FCAP FCR TRVG FSCE

0
Public Art Installation to be Unveiled at Edmonton Brewery District

2018-06-12 globenewswire
EDMONTON, Alberta, June 12, 2018 (GLOBE NEWSWIRE) -- First Capital Realty will unveil the inaugural public art installation “Carbon Copy” at the Edmonton Brewery District on Friday, June 15, 2018. The sculpture, created by Alberta-based artists Caitlind r.c. Brown and Wayne Garrett, evokes the possibility of renewed understanding through a shift in perspective. “Carbon Copy” transforms a re-appropriated 1988 Plymouth Caravelle K-Car into an illuminated obelisk, a monument to today’s evolving car culture, and a glitch in our regular understanding of everyday life.
FCR.DB.H FCR.DB.I FCRGF FCR.DB.J FCR FCR.DB.E

3
Gazit Horizons Invests an additional $63 million in New York City and Boston

2018-06-06 globenewswire
MIAMI, June 06, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), a leading global real estate company focused on the ownership, development and management of shopping centers and mixed-use properties in major urban markets, announced today that its wholly owned subsidiary, Gazit Horizons, Inc., has entered into a joint venture for the leasehold interest in Ceasar’s Bay Bazaar, a 300,000 square foot shopping center on 14 acres along the Brooklyn, New York waterfront, and has also acquired two additional assets in Boston, Massachusetts.
REG FCR.DB.H REG.PRG FCR.DB.I XKE REG.PRF FCR.DB.J GZT DTK FCRGF GZT FCR FCR.DB.E

3
Gazit-Globe Reports Strong Operational Results in First Quarter 2018

2018-05-28 globenewswire
TEL AVIV, Israel, May 28, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced today its financial results for the first quarter ended March 31, 2018.
REG FCR.DB.H REG.PRG FCR.DB.I REG.PRF FCR.DB.J GZT DTK FCRGF GZT FCAP FCR FCR.DB.E

3
Gazit Globe Announces Date for Q1 2018 Results Conference Call

2018-05-03 globenewswire
TEL-AVIV, Israel, May 03, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, invites you to participate at 10:00 am US EDT/ 5:00 pm Israel Time on Tuesday, May 29, 2018 in a live conference call with senior management to discuss the Company’s first quarter results ended March 31, 2018.
REG FCR.DB.H REG.PRG FCR.DB.I FCRGF REG.PRF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

3
Gazit-Globe Files Annual Report on Form 20-F for the Year Ended December 31, 2017

2018-05-02 globenewswire
TEL-AVIV, Israel, May 02, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission (the “SEC”).
REG FCR.DB.H REG.PRG FCR.DB.I FCRGF REG.PRF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

133
10 Best Stocks Under $10

2018-04-24 investorplace
Good things come in small packages goes the saying. Nowhere is that truer than in the markets where stocks under $10 grow to be $100 and possibly even $1,000 over time.
REG FCR.DB.H FCR.DB.I FXFLF WETF BXG VAC FXFHF FAXXF FCR.DB.J AY DXJ FSC GZT OAK HEDJ FRFHF OSLE FRFFF JILL SIRI ARCO AMZN FRFZF FAXRF FRFXF FCR.DB.E MCD REG.PRG REG.PRF BBX IBN FRFGF AQN OCSL FCRGF GZT ICICIBANK FSCFL EDE 532174 FCAP FCR TRVG FSCE

3
Gazit-Globe divulga os sólidos resultados financeiros de 2017

2018-03-29 globenewswire
TEL-AVIV, Israel, March 29, 2018 (GLOBE NEWSWIRE) -- A Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), empresa global líder do ramo imobiliário focada na propriedade, administração e desenvolvimento de propriedades de varejo e uso misto em mercados urbanos, anunciou hoje seus resultados financeiros para o final do ano e quarto trimestre, encerrados em 31 de dezembro de 2017.
REG FCR.DB.H REG.PRG FCR.DB.I FCRGF REG.PRF GZT FCR.DB.J GZT FCR FCR.DB.E

3
Gazit-Globe Reports Strong Financial Results in 2017

2018-03-28 globenewswire
TEL-AVIV, Israel, March 28, 2018 (GLOBE NEWSWIRE) -- Gazit-Globe (NYSE:GZT) (TSX:GZT) (TASE:GZT), a leading global real estate company focused on the ownership, management and development of retail and mixed use properties in urban markets, announced today its financial results for the year-end and fourth quarter ended December 31, 2017.
REG FCR.DB.H REG.PRG FCR.DB.I FCRGF REG.PRF GZT FCR.DB.J GZT DTK FCR FCR.DB.E

3
Israel real estate developer Gazit-Globe Q4 profit edges lower

2018-03-28 reuters
* The company said on Tuesday it earned 583 million shekels ($167 million) in the quarter compared with 587 million a year earlier.
REG FCR.DB.H REG.PRG FCR.DB.I FCRGF REG.PRF FCR.DB.J FCR FCR.DB.E

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...